Skip to main content
SpringerLink
Log in

Behandlung der Migräne

Neue Medikamente zur Therapie der Migräneattacke und Migräneprophylaxe

  • Zertifizierte Fortbildung Neurologie
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Diener HC, Förderreuther S, Kropp P et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2022, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien

  2. Goadsby PJ et al. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8

  3. Farkkila M et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405-13

  4. Ferrari MD et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170-8

  5. Kuca B et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018;91(24):e2222-e32

  6. Goadsby PJ et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894-904

  7. Lipton RB et al. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain. 2020;21(1):20

  8. Ashina M et al. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia. 2021;41(3):294-304

  9. Maiti R et al. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis. J Clin Pharmacol. 2021;61(12):1534-44

  10. Shapiro RE et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90

  11. Brandes JL et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343-57

  12. Olesen J et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104-10

  13. Lipton RB et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142-9

  14. Croop R et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-45

  15. Yang C-P et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Network Open. 2021;4(10):e2128544-e

  16. Gao B et al. Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials. Front Pharmacol. 2019;10:1577

  17. Hutchinson S et al. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. Neurol Ther. 2021;10(1):235-49

  18. Dodick DW et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019;381(23):2230-41

  19. Croop R et al. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153-63

  20. Diener H-C et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie [https://www.dgn.org/leitlinien]. Deutsche Gesellschaft für Neurologie; 2018

  21. Deng H et al. Efficacy and safety of calcitonin gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):57

  22. Soni P, Chawla E. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis. Clin Neurol Neurosurg. 2021;209:106893.

  23. Mechtler L et al. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Front Neurol. 2022;12:788159

  24. Wang Xet al. Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. Front Pharmacol. 2021;12:649143

  25. de Vries Lentsch S et al. Blood Pressure in Migraine Patients Treated With Monoclonal Anti-CGRP (receptor) Anti-bodies: A Prospective Follow-up Study. Neurology. 2022;99(17):e1897-e1904

  26. Ailani J et al. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical prac-tice. Headache: The Journal of Head and Face Pain. 2021;61(7):1021-39

  27. Sacco S et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. The Journal of Headache and Pain. 2022;23(1):67

  28. Diener H-C et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. Neurologi-cal Research and Practice. 2020;2(1):11

  29. Tepper SJ et al. Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations. Headache. 2022;62(4):420-35

  30. Overeem LH et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in mi-graine: A multi-center retrospective cohort study. Cephalalgia. 2022;42(4-5):291-301

  31. Reuter U et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2021:3331024211053571.

  32. McAllister P et al. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. J Headache Pain. 2022;23(1):22.

  33. Ashina M et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716-25

  34. Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60

  35. Woodhead JL et al. Comparing the Liver Safety Profiles of Four Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling. Toxicol Sci. 2022;188(1):108-116

Download references

Author information

Authors and Affiliations

  1. Institut für Medizinische Informatik, Biometrie und Epidemiologie (IMIBE), Medizinische Fakultät der Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany

    Hans-Christoph Diener

  2. Klinik und Poliklinik für Neurologie, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Germany

    Dagny Holle-Lee

Authors
  1. Hans-Christoph Diener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dagny Holle-Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Christoph Diener.

Ethics declarations

Der Autor und die Autorin erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: H.-C. Diener hat Honorare für die Teilnahme an Advisory Boards oder Vorträge erhalten von: Abbvie, Ipsen Pharma, Lilly, Lundbeck, Novartis, Pfizer, TEVA, Weber & Weber und Medscape. Die Kopfschmerzforschung von H.-C. Diener wird unterstützt von der DFG und dem BMBF. D. Holle-Lee hat Honorare für die Teilnahme an Avisory Boards oder Vorträge erhalten von: Abbvie, Esanum, Lilly, Lundbeck, Novartis, Pfizer, TEVA, Zuellig.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diener, HC., Holle-Lee, D. Neue Medikamente zur Therapie der Migräneattacke und Migräneprophylaxe. InFo Neurologie 24, 34–40 (2022). https://doi.org/10.1007/s15005-022-3087-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-022-3087-5

Search

Navigation